Antipsychotic Medication and Risk of Metabolic Disorders in People With Schizophrenia: A Longitudinal Study Using the UK Clinical Practice Research Datalink

Abstract Background and Hypothesis Antipsychotics are first-line drug treatments for schizophrenia. When antipsychotic monotherapy is ineffective, combining two antipsychotic drugs is common although treatment guidelines warn of possible increases in side effects. Risks of metabolic side effects with antipsychotic polypharmacy have not been fully investigated. This study examined associations between antipsychotic polypharmacy and risk of developing diabetes, hypertension, or hyperlipidemia in adults with schizophrenia, and impact of co-prescription of first- and second-generation antipsychotics. Study Design A population-based prospective cohort study was conducted in the United Kingdom using linked primary care, secondary care, mental health, and social deprivation datasets. Cox proportional hazards models with stabilizing weights were used to estimate risk of metabolic disorders among adults with schizophrenia, comparing patients on antipsychotic monotherapy vs polypharmacy, adjusting for demographic and clinical characteristics, and antipsychotic dose. Study Results Median follow-up time across the three cohorts was approximately 14 months. 6.6% developed hypertension in the cohort assembled for this outcome, with polypharmacy conferring an increased risk compared to monotherapy, (adjusted Hazard Ratio = 3.16; P = .021). Patients exposed to exclusive first-generation antipsychotic polypharmacy had greater risk of hypertension compared to those exposed to combined first- and second-generation polypharmacy (adjusted HR 0.29, P = .039). No associations between polypharmacy and risk of diabetes or hyperlipidemia were found. Conclusions Antipsychotic polypharmacy, particularly polypharmacy solely comprised of first-generation antipsychotics, increased the risk of hypertension. Future research employing larger samples, follow-up longer than the current median of 14 months, and more complex methodologies may further elucidate the association reported in this study.

[1]  S. Davies,et al.  Visualizing classification of drugs used in psychotic disorders: A ‘subway map’ representing mechanisms, established classes and informal categories , 2022, Journal of psychopharmacology.

[2]  S. Cooper,et al.  Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology , 2019, Journal of psychopharmacology.

[3]  M. Scarselli,et al.  Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences , 2018, Pharmacology & therapeutics.

[4]  L. Rojo,et al.  Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. , 2015, Pharmacological research.

[5]  K. Bhaskaran,et al.  Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.

[6]  C. Correll,et al.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder , 2015, World psychiatry : official journal of the World Psychiatric Association.

[7]  Maudsley Nhs Trust,et al.  The Maudsley Prescribing Guidelines in Psychiatry , 2015 .

[8]  P. Ho,et al.  Estimating the effects of time‐varying exposures in observational studies using Cox models with stabilized weights adjustment , 2014, Pharmacoepidemiology and drug safety.

[9]  P. Mortensen,et al.  Excess early mortality in schizophrenia. , 2014, Annual review of clinical psychology.

[10]  S. Stahl Antipsychotic polypharmacy: never say never, but never say always , 2012, Acta psychiatrica Scandinavica.

[11]  T. Wetterling,et al.  The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs , 2011, International clinical psychopharmacology.

[12]  J. Langan,et al.  Antipsychotic polypharmacy: review of mechanisms, mortality and management , 2010 .

[13]  M. Tancer,et al.  The story of antipsychotics: Past and present , 2009, Indian journal of psychiatry.

[14]  Mondher Toumi,et al.  Predictors of employment status change over 2 years in people with schizophrenia living in Europe , 2009, Epidemiology and Psychiatric Sciences.

[15]  M. Kenward,et al.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls , 2009, BMJ : British Medical Journal.

[16]  C. Correll,et al.  Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. , 2009, Schizophrenia bulletin.

[17]  Henry A. Nasrallah,et al.  Schizophrenia, “Just the Facts” What we know in 2008. 2. Epidemiology and etiology , 2008, Schizophrenia Research.

[18]  Alexander L. Miller,et al.  The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. , 2007, The Journal of clinical psychiatry.

[19]  L. Moore,et al.  The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards – a cluster randomized controlled trial , 2007, Psychological Medicine.

[20]  D. Nutt,et al.  Panic and hypertension: brothers in arms through 5-HT? , 2007, Journal of psychopharmacology.

[21]  C. Correll,et al.  Does antipsychotic polypharmacy increase the risk for metabolic syndrome? , 2007, Schizophrenia Research.

[22]  Peter B. Jones,et al.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). , 2006, Archives of general psychiatry.

[23]  Patrick Royston,et al.  Multiple Imputation of Missing Values: Update of Ice , 2005 .

[24]  C. Correll,et al.  Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics , 2005, BMC psychiatry.

[25]  R. Holt,et al.  Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia , 2004, British Journal of Psychiatry.

[26]  P. Lelliott,et al.  The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK , 2002 .

[27]  N. Keltner,et al.  Biological perspectives. Aripiprazole: a third generation of antipsychotics begins? , 2002, Perspectives in psychiatric care.

[28]  Philip Seeman,et al.  Atypical Antipsychotics: Mechanism of Action , 2002, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[29]  E. Laska,et al.  Recovery from psychotic illness: A 15- and 25-year international follow-up study , 2001, British Journal of Psychiatry.

[30]  W. Shen A history of antipsychotic drug development. , 1999, Comprehensive psychiatry.

[31]  World federation of societies of biological psychiatry , 1990, Biological Psychiatry.